Shares of Pacira Pharmaceuticals (NASDAQ: PCRX) tumbled 5.46% in after-hours trading on Tuesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's performance fell short of market expectations in key areas, prompting a negative reaction from investors.
Pacira reported total revenues of $181.1 million for the quarter, missing the analyst consensus estimate of $183 million. This represents a marginal increase of 1.73% compared to the same period last year. Despite the revenue miss, the company's adjusted earnings per share (EPS) of $0.74 beat the estimated $0.71, showcasing some resilience in its bottom line.
However, investors seemed more concerned about Pacira's net loss of $4.8 million for the quarter and its decision to narrow its full-year 2025 revenue guidance. The company now expects total revenue between $730 million and $750 million, down from the previous range of $725 million to $765 million. This adjustment, coupled with the Q2 performance, appears to have dampened market sentiment, leading to the significant after-hours decline in stock price.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。